In order to develop and test approaches for both active and passive immunization against natural HIV infection, it is imperative to understand how antibody mediates neutralization of HIV. Virus neutralization is a function of at least three variables: the antibody, the target cell and the virus. It is the aim of this proposal to understand how each of these variables contributes to virus/cell interaction and how changes in these parameters affect the ability of antibodies to inhibit virus infectivity. Experiments are designed to explore these variables based on the """"""""Velcro Hypothesis"""""""" which proposes that HIV, like many other viruses, attaches to cells through a multiplicity of molecules on its surface. Thus, the expression and interaction of the various receptors and ligands, on the surface of the virion and on the surface of the target cell, influence the efficiency with which a particular antibody or mixture of antibodies, will prevent infection. To test this hypothesis the investigator has designed experiments that will provide information about how changes in the combination of antibodies, target cells and viruses will affect HIV binding, infectivity and neutralization. The experiments are designed to address four related area:
Aim #1 will define the critical biologic parameters of the antibodies, target cells and viruses commonly used to study HIV neutralization.
Aim #2 will focus on how the choice of antibody, target cell and virus will affect the degree of neutralization measured.
Aim #3 will determine how and which monoclonal antibodies (or combinations of monoclonal antibodies) to HIV and to adhesion molecules are most effective at neutralizing various virus/target cell combinations. Finally, Aim #4 will test sera of immunized animals and humans, and infected humans, for neutralizing antibodies using various virus/target cell combinations. This final section will provide important insights into the role of neutralizing antibodies in protection against infection and the ability of various vaccines to induce neutralizing antibodies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI032424-06
Application #
2457745
Study Section
Special Emphasis Panel (ZRG5-ARRA (01))
Project Start
1991-09-30
Project End
1999-07-31
Budget Start
1997-08-01
Budget End
1998-07-31
Support Year
6
Fiscal Year
1997
Total Cost
Indirect Cost
Name
New York University
Department
Pathology
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016
Chien Jr, Peter C; Cohen, Sandra; Kleeberger, Cynthia et al. (2002) High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 glycoprotein 120 are associated with faster disease progression. J Infect Dis 186:205-13
Zhang, Peng Fei; Bouma, Peter; Park, Eun Ju et al. (2002) A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J Virol 76:644-55
Jeffs, S A; Gorny, M K; Williams, C et al. (2001) Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120. Immunol Lett 79:209-13
York, J; Follis, K E; Trahey, M et al. (2001) Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1. J Virol 75:2741-52
Verrier, F; Nadas, A; Gorny, M K et al. (2001) Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J Virol 75:9177-86
Hioe, C E; Chien Jr, P C; Lu, C et al. (2001) LFA-1 expression on target cells promotes human immunodeficiency virus type 1 infection and transmission. J Virol 75:1077-82
Nyambi, P N; Mbah, H A; Burda, S et al. (2000) Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol 74:7096-107
Nyambi, P N; Nadas, A; Mbah, H A et al. (2000) Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J Virol 74:10670-80
Taniguchi, Y; Zolla-Pazner, S; Xu, Y et al. (2000) Human monoclonal antibody 98-6 reacts with the fusogenic form of gp41. Virology 273:333-40
Hioe, C E; Jones, G J; Rees, A D et al. (2000) Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120. AIDS Res Hum Retroviruses 16:893-905

Showing the most recent 10 out of 57 publications